Article Text

Download PDFPDF
Autoantibodies to osteoprotegerin are associated with increased bone resorption in rheumatoid arthritis
  1. Barbara Hauser1,
  2. Philip L Riches1,
  3. Tamara Gilchrist1,
  4. Micaela R Visconti1,
  5. James F Wilson2,
  6. Stuart H Ralston1
  1. 1 Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
  2. 2 Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK
  1. Correspondence to Professor Stuart H Ralston, Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK; stuart.ralston{at}ed.ac.uk

Statistics from Altmetric.com

Periarticular and systemic bone loss are important complications of rheumatoid arthritis (RA).1 The pathogenesis is complex involving local and systemic release of cytokines which promote osteoclastic bone resorption2; production of receptor activator of nuclear factor κB (NFκB) ligand (RANKL) by activated T cells3 and immobility, corticosteroid use4 and the direct osteoclast activating effects of antibodies directed against citrullinated proteins (ACPA).5 ,6 We previously reported the occurrence of severe osteoporosis in a patient with autoimmune disease who had developed autoantibodies to the bone protective protein osteoprotegerin (OPG).7 In this study, we screened for the presence of similar autoantibodies in RA and evaluated their clinical significance. We developed an ELISA for autoantibodies to OPG, by coating 96-well plates with recombinant human OPG as the capture antigen. Following the addition of patient samples to each well and multiple wash steps, bound OPG antibodies were detected by a peroxidase conjugated, anti-human IgG antibody (Jackson Immuno Research Labs , 109-035-127). Concentrations of OPG antibody were then …

View Full Text

Footnotes

  • Contributors Study concept and design: BH, PLR and SHR. Acquisition of data: BH, JFW and SHR. Analysis and interpretation of data: BH, TG, MRV, PLR and SHR. Obtained funding: BH, JFW and SHR. Study supervision: PLR and SHR.

  • Funding Arthritis Research UK (19299).

  • Competing interests SHR and PLR are inventors on a patent application on the use of OPG antibodies as a diagnostic marker for bone disease and vascular calcification.

  • Ethics approval Lothian Research Ethics Committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.